Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
Integra LifeSciences' post-2025 baseline shows revenue growth decelerating to 2.3% in Q3 2026 from 11.5% in Q4 2024, with gross margins swinging as widely as 49.5% to 57.2% over ten quarters, suggesting manufacturing remediation costs in Tissue Reconstruction may be structural rather than transitory.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $0.59+5.9% vs $0.56 | $411M-0.5% vs $413M |
Q3 2026 Jul 29, 2026 | $0.56+16.5% vs $0.48 | $419M+0.3% vs $418M |
Q2 2026 May 5, 2026 | $0.54+31.7% vs $0.41 | $392M+2.6% vs $382M |
Q1 2026 Feb 26, 2026 | $0.83+5.1% vs $0.79 | $435M+1.2% vs $430M |
Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET.
Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to underperform, though upcoming product relaunches and market normalization could drive recovery. Valuation appears undemanding, with EBITDA margin expected to exceed 20% in 2025 and double-digit FCF margins possible by 2028.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 2, 2026 disclosure c.
Benchmark IART against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Integra LifeSciences Holdings Corporation (IART)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.55 | $1.05B | 81.82 | 1.53% | 0.79% | 1.24% | — | |
| $11.14 | $1.29B | -10.69 | 8.28% | -16.78% | -35.81% | — | |
| $55.02 | $2.8B | 184.20 | 14.88% | 2.52% | 2.93% | — | |
| $287.47 | $41.17B | -251.44 | 35.9% | -5.66% | -9.18% | — | |
| $84.49 | $5.04B | 31.86 | 11.66% | 9.94% | 9.65% | — | |
| $76.10 | $1.74B | 27.72 | 13.53% | 23.51% | 15.33% | 1.04% |
Integra LifeSciences Holdings Corporation (IART) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Integra LifeSciences Holdings Corporation (IART) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Oct 19, 2026·SEC
Oct 9, 2026·SEC
Get notified when IART posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Integra LifeSciences Holdings Corporation (IART) stock FAQ — growth, dividends, profitability & financials explained
Integra LifeSciences Holdings Corporation (IART) reported $1.66B in revenue over the trailing twelve months. Revenue was $1.64B in fiscal year 2025. That is 12383% more than the $13.1M of fiscal year 1996.
Integra LifeSciences Holdings Corporation (IART) grew revenue by 0.8% over the trailing twelve months, compared with the twelve months before.
Yes. Integra LifeSciences Holdings Corporation (IART) earned $13.0M in net income over the trailing twelve months (a 0.8% net margin).
Integra LifeSciences Holdings Corporation (IART) had a return on equity (ROE) of 1.2% over the trailing twelve months. That is below the market's typical 10-15%.
Integra LifeSciences Holdings Corporation (IART) generated $98.7M in free cash flow over the trailing twelve months.